Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense of $0 in Q2 FY2026

Q2 FY2026 income tax expense was $0.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Income Tax Expense vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Income tax expense amounts to 0.0% of revenue for ATTO, versus a peer median of 0.0%.
ATTO Competitors
Income Tax Expense for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$1.08M USD+195.7%+156.1%—
CNTBConnect Biopharma Holdings LimitedFY2025$197K USD-11.7%-12.9%307.8%
ANABAnaptysBio, Inc.LTM Mar 2026$160K USD+240.4%+89.8%0.1%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€4K EUR+100.6%——
ATTOAttovia Therapeutics, Inc.FY2025$0 USD——0.0%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$0 USD———
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
EVMNEvommune, Inc.LTM Mar 2026$0 USD——0.0%
QTTBQ32 Bio Inc.LTM Mar 2026$0 USD-100.0%—0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 USD———
ALMSAlumis Inc. Common StockLTM Jun 2026-$1.76M USD+79.5%—23.7%
Peer median (excluding ATTO) —+90.1%+89.8%0.0%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.